In late 2025, the detection of Minimal Residual Disease (MRD) has become a cornerstone of post-operative care in Germany, helping to identify patients at a high risk of recurrence before tumors become visible on radiographic scans. By monitoring for the persistence of tumor-specific mutations after surgical resection or chemotherapy, oncologists can make informed decisions regarding the necessity and intensity of adjuvant treatments. This proactive approach is particularly vital in the management of colorectal and breast cancers, where early detection of molecular relapse can significantly alter the patient's long-term prognosis. The Germany Liquid Biopsy Sector highlights that clinical trials like the SURVIVE study are currently validating the survival benefits of liquid biopsy-guided follow-up care in German medical university hospitals. This real-time monitoring capability allows for the adjustment of treatment protocols based on the biological response of the individual's cancer, fostering a more dynamic and personalized healthcare model.

Frequently Asked Questions

Q. What is Minimal Residual Disease (MRD)? A. MRD refers to the small number of cancer cells that remain in the body after treatment, which are not detectable by traditional imaging but can be found via ctDNA analysis.

Q. How much sooner can liquid biopsy detect a recurrence? A. Clinical studies in Germany suggest that molecular marke